NCT07142642View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

November 22, 2025

Study Completion Date

November 22, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

Teprotumumab

Administered via IV infusion.

DRUG

Placebo

Administered via IV infusion.

Trial Locations (1)

200031

Huashan Hospital, Fudan University, Minhang

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY